Cover Image
市場調查報告書

中國的濾泡刺激素 (FSH) 市場分析

Investigation Report on China Follicle-Stimulating Hormone (FSH) Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 334088
出版日期 內容資訊 英文 25 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的濾泡刺激素 (FSH) 市場分析 Investigation Report on China Follicle-Stimulating Hormone (FSH) Market, 2010-2019
出版日期: 2015年07月02日 內容資訊: 英文 25 Pages
簡介

濾泡刺激素 (FSH) 自打入中國市場以後便急速成長。年度銷售額從2006年的200萬人民幣,到2014年達成2億1,500萬人民幣,達到了年複合成長率率84.2%的成長。

本報告提供中國的濾泡刺激素 (FSH) 市場相關調查分析,提供您市場規模,競爭情形,各企業的零售價格,市場預測等相關的系統性資訊。

第1章 濾泡刺激素 (FSH) 的相關概念

  • 適應
  • 全球市場銷售情形

第2章 中國的濾泡刺激素 (FSH) 的市場簡介

  • 中國的濾泡刺激素 (FSH) 的專利·核準情況
  • 主要製造商
  • 市場規模

第3章 中國的濾泡刺激素 (FSH) 銷售分析

  • 銷售額
  • 銷售額數量

第4章 中國的濾泡刺激素 (FSH) 主要廠商的市場佔有率分析

  • 市場佔有率:不同銷售額
  • 市場佔有率:銷售額各數量

第5章 中國的濾泡刺激素 (FSH) 的各劑型分析

  • 市場佔有率 (各劑型) :不同銷售額
  • 市場佔有率 (各劑型) :銷售額各數量

第6章 中國的濾泡刺激素 (FSH) 的醫院用標準價格

第7章 中國市場的濾泡刺激素 (FSH) 的主要製造商

  • Livzon Pharmaceutical Group Co., Ltd
  • Merck Serono (瑞士)
  • IBSA Institut Biochimique SA (瑞士)

第8章 中國的濾泡刺激素 (FSH) 的市場預測

  • 市場規模的預測
  • 競爭情形的預測

圖表

目錄
Product Code: 1507249

According to WHO's evaluation, one in seven couples suffer from fertility which influences about 10%-15% of the world population. According to a survey, the number of patients with fertility accounts for 10% of married people, being double of 4.8% in 1984. The incidence of fertility in young people has increased and it is 15%-20% among women of childbearing age. For patients with hypothalamic-pituitary dysfunction including polycystic ovary syndrome, FSH can promote follicular development while in the case of blocked fallopian tube, unexplained fertility and fertility caused by male factor, FSH can do so in the assistive technology used to conceive the child.

FSH brought in a global sales value of over USD 1.2 billion in 2013 to which Gonal-f (FSHα) made by Merck Serono contributed USD 813 million with a market share of 63% while Puregon (FSHβ) of Merck contributed USD 481 million with a market share of 37%. FSH develops fast after entering China, annual sales value rising from less than CNY 2 million in 2006 to CNY 215 million in 2014 and CAGR during this period reaching 84.2%. Merck Serono (rhFSHα), Livzon Pharmaceutical Group Co., Ltd (UFSH), IBSA (UFSH) and Organon (rhFSHβ) dominate the Chinese market, among which Livzon Pharmaceutical Group Co., Ltd has the largest market share of about 59% for sales value in 2014.

As the number of patients suffering from infertility is huge in China, FSH has good market prospects.

Readers can get at least the following information from this report:

  • market size of FSH in China
  • competitive landscape of FSH in Chinese market
  • price of FSH made by different enterprises in China
  • market outlook of FSH in China

The author suggests the following groups of people purchase this report:

  • manufacturers of endocrine regulator
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of FSH

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of FSH in China

  • 2.1. Patent and Approval Status of FSH in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of FSH in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of FSH in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of FSH in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of FSH in Chinese Hospitals in 2014

  • 6.1. IBSA Institut Biochimique SA (SW) (Trade Name: Fostimon)
  • 6.2. Livzon Pharmaceutical Group Co., Ltd (Trade Name: Hemei)
  • 6.3. Merck Serono (Switzerland) (Trade Name: Gonal-f)

7. Major Manufacturers of FSH in Chinese Market, 2010-2014

  • 7.1. Livzon Pharmaceutical Group Co., Ltd
  • 7.2. Merck Serono (Switzerland)
  • 7.3. IBSA Institut Biochimique SA (Switzerland)

8. Market Outlook of FSH in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of FSH in China
  • Chart Sales Status of FSH in China, 2010-2014
  • Chart Sales Value of FSH in China, 2010-2014
  • Chart Sales Value of FSH in Some Regions in China, 2010-2014
  • Chart Sales Volume of FSH in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of FSH for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of FSH Made by Livzon in China, 2010-2014
  • Chart Sales Value and Market Share of FSH Made by IBSA Institut(SW) in China, 2010-2014
  • Chart Sales Value and Market Share of FSH Made by Merck Serono (Switzerland) in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of FSH for Sales Volume in China, 2010-2014
  • Chart Sales Volume and Market Share of FSH Made by Livzon in China, 2010-2014
  • Chart Sales Volume and Market Share of FSH Made by IBSA Institut(SW) in China, 2010-2014
  • Chart Price of FSH Made by IBSA Institut Biochimique SA (SW) in Some Cities in China in 2014
  • Chart Price of FSH Made by Livzon Pharmaceutical Group Co., Ltd in Some Cities in China in 2014
  • Chart Price of FSH Made by Merck Serono (Switzerland) in Some Cities in China in 2014
Back to Top